[Sarcoidosis--immunological features and clinical issues].
Handa
Tomohiro
T
Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University.
Nagai
Sono
S
Ohta
Kousuke
K
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D015551:Autoimmunity; D001608:Beryllium / Q000009:adverse effects; D015415:Biomarkers / Q000097:blood; D016516:CD4-CD8 Ratio; D002118:Calcium / Q000378:metabolism; D016207:Cytokines; D004781:Environmental Exposure / Q000009:adverse effects; D000068800:Etanercept; D006684:HLA-DR Antigens / Q000235:genetics; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D000069285:Infliximab; D008264:Macrophages / Q000276:immunology; D008727:Methotrexate / Q000008:administration & dosage; D009113:Muramidase / Q000097:blood; D007703:Peptidyl-Dipeptidase A / Q000097:blood / Q000235:genetics; D011239:Prednisolone / Q000008:administration & dosage; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D012507:Sarcoidosis / Q000175:diagnosis / Q000209:etiology / Q000276:immunology / Q000628:therapy; D013601:T-Lymphocytes / Q000276:immunology
D000911:Antibodies, Monoclonal; D015415:Biomarkers; D016207:Cytokines; D006684:HLA-DR Antigens; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D018124:Receptors, Tumor Necrosis Factor; D011239:Prednisolone; D000069285:Infliximab; D009113:Muramidase; D007703:Peptidyl-Dipeptidase A; D000068800:Etanercept; D001608:Beryllium; D002118:Calcium; D008727:Methotrexate